argenx (NASDAQ:ARGX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

A number of other research analysts have also recently commented on the stock. Wedbush increased their target price on shares of argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Guggenheim assumed coverage on shares of argenx in a report on Friday, February 22nd. They issued a “buy” rating and a $157.00 target price for the company. ValuEngine raised shares of argenx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Stifel Nicolaus reissued a “buy” rating on shares of argenx in a report on Monday, February 4th. Finally, SunTrust Banks reissued a “buy” rating on shares of argenx in a report on Friday, January 18th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. argenx currently has a consensus rating of “Buy” and an average price target of $144.27.

Shares of ARGX stock traded up $5.24 on Wednesday, reaching $126.00. The company had a trading volume of 126,942 shares, compared to its average volume of 175,041. The stock has a market capitalization of $3.91 billion, a P/E ratio of -53.62 and a beta of 1.12. argenx has a one year low of $63.81 and a one year high of $135.58.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its stake in argenx by 0.3% during the 4th quarter. FMR LLC now owns 3,487,052 shares of the company’s stock valued at $335,001,000 after acquiring an additional 12,003 shares in the last quarter. BB Biotech AG increased its holdings in argenx by 20.4% in the 4th quarter. BB Biotech AG now owns 884,739 shares of the company’s stock worth $84,997,000 after acquiring an additional 150,000 shares during the last quarter. venBio Select Advisor LLC increased its holdings in argenx by 13.8% in the 4th quarter. venBio Select Advisor LLC now owns 860,000 shares of the company’s stock worth $82,620,000 after acquiring an additional 104,585 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in argenx by 143.6% in the 1st quarter. Artisan Partners Limited Partnership now owns 770,336 shares of the company’s stock worth $96,169,000 after acquiring an additional 454,046 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in argenx by 0.6% in the 1st quarter. Jennison Associates LLC now owns 509,868 shares of the company’s stock worth $63,652,000 after acquiring an additional 2,897 shares during the last quarter. 63.62% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Recommended Story: What are municipal bonds?

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.